Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt

authors:

avatar Amel Abdel Magied El-Faramawy 1 , * , avatar Omnia Fathy El-Rashidy 2 , avatar Perihan Hamdy Tawfik 2 , avatar Galal Helmy Hussein 2

The Pediatrics Department, Faculty of Medicine, Ain Shams University, amelhome4@gmail.com, Egypt
The Clinical Pathology Department, Faculty of Medicine, Ain Shams, University, Egypt
Hepatitis Monthly: Vol.12, issue 4; 286-291
article type: Research Article
received: September 22, 2011
accepted: March 2, 2012
DOI: https://doi.org/10.5812/hepatmon.852

how to cite: Magied El-Faramawy A, El-Rashidy O, Tawfik P, Hussein G. Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt. Hepat Mon. 2012;12(4): 286-291. https://doi.org/10.5812/hepatmon.852.

Abstract

Background: Despite progress made in the prevention of transfusion-transmitted infections (TTI) over the last few years, they continue to be a problem in many parts of the world, particularly in multitransfused patients.
Objectives: The aim of this study was to estimate the prevalence of hepatitis B virus (HBV), hepatitis C virus (HCV), and to evaluate the screening and vaccination program among our cohort of multitransfused children from Qena, Upper Egypt.
Patients and Methods: One-hundred children suffering from diseases requiring repeated blood transfusions were included in the study. They were classified into group 1, which included 67 children with thalassemia, and group 2, which included 33 children with hemophilia. Screening for hepatitis B surface antigen, hepatitis B surface antibody, hepatitis B core antibody and antibody to HCV was done using a second-generation enzyme-linked immunosorbent assay technique.
Results: Only 12% of all patients were either acutely or chronically infected with HBV. 46% were immune due to previous vaccination, whereas 39% of patients were not protected from HBV infection. HCV antibodies were positive in 45% of cases. Seventy-eight patients had a complete hepatitis B vaccination in the form of three doses as documented by birth certificate. Thirty-six patients mentioned history suggestive of hepatitis. The prevalence of the studied hepatitis markers was similar in both the thalassemia and hemophilia groups of children.
Conclusions: Transfusion-transmitted hepatitis is still a major problem for multitransfused children in Egypt. More effort is required to reduce the infection rate through proper screening of blood and blood products, strict emphasis on receiving the vaccine, regular follow-up for those children with a hepatitis B antibody titer, and providing booster doses for those in need.

  • Implication for health policy/practice/research/medical education:
    As Egypt is a country of intermediate prevalence regarding HBV and of high prevalence regarding HCV infection, great effort should be made to prevent and control these infections .updating the knowledge about the prevalence of these infections particularly among the high risk groups is important to assess the efficacy of preventive measures and to highlight weak points in the strategy aiming to decrease the infection rate. This study is recommended to all clinicians involved in treatment of polytransfused patients for better outcome.
  • Please cite this paper as:
    El-Faramawy AA, El-Rashidy OF, Tawfik PH, Hussein GH. Transfusion Transmitted Hepatitis: Where Do We Stand Now? A One Center Study in Upper Egypt. Hepat Mon. 2012;12(4): 286-291. DOI: 10.5812/hepatmon.852

Copyright © 2012 Kowsar Corp. All rights reserved.

Full Text

Full text is available in PDF